Aclaris Therapeutics, Inc.

NasdaqGS:ACRS Stock Report

Market Cap: US$292.1m

Aclaris Therapeutics Valuation

Is ACRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ACRS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACRS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACRS?

Key metric: As ACRS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ACRS. This is calculated by dividing ACRS's market cap by their current revenue.
What is ACRS's PS Ratio?
PS Ratio10.8x
SalesUS$27.08m
Market CapUS$292.07m

Price to Sales Ratio vs Peers

How does ACRS's PS Ratio compare to its peers?

The above table shows the PS ratio for ACRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.2x
RVNC Revance Therapeutics
1.2x20.6%US$321.0m
ETON Eton Pharmaceuticals
9.7x34.8%US$337.2m
XERS Xeris Biopharma Holdings
2.7x17.2%US$511.3m
FULC Fulcrum Therapeutics
3.1x-88.2%US$258.4m
ACRS Aclaris Therapeutics
9.8x5.5%US$292.1m

Price-To-Sales vs Peers: ACRS is expensive based on its Price-To-Sales Ratio (9.8x) compared to the peer average (4.2x).

Price to Sales Ratio vs Industry

How does ACRS's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

67 CompaniesPrice / SalesEstimated GrowthMarket Cap
VTRS Viatris
1x-1.1%US$14.90b
OGN Organon
0.6x0.02%US$3.88b
PRGO Perrigo
0.8x3.4%US$3.49b
BHC Bausch Health Companies
0.3x1.5%US$2.81b
ACRS 10.8xIndustry Avg. 3.1xNo. of Companies67PS048121620+
67 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ACRS is expensive based on its Price-To-Sales Ratio (9.8x) compared to the US Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is ACRS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACRS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10.8x
Fair PS Ratio0.3x

Price-To-Sales vs Fair Ratio: ACRS is expensive based on its Price-To-Sales Ratio (9.8x) compared to the estimated Fair Price-To-Sales Ratio (0.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACRS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.73
US$10.00
+266.3%
51.0%US$20.00US$5.00n/a6
Dec ’25US$4.07
US$7.60
+86.7%
42.1%US$13.00US$3.00n/a5
Nov ’25US$2.09
US$1.55
-25.8%
29.4%US$2.00US$1.00n/a4
Oct ’25US$1.18
US$1.55
+31.4%
29.4%US$2.00US$1.00n/a4
Sep ’25US$1.18
US$1.55
+31.4%
29.4%US$2.00US$1.00n/a4
Aug ’25US$1.32
US$1.84
+39.4%
38.5%US$3.00US$1.00n/a5
Jul ’25US$1.15
US$1.84
+60.0%
38.5%US$3.00US$1.00n/a5
Jun ’25US$1.03
US$1.84
+78.6%
38.5%US$3.00US$1.00n/a5
May ’25US$1.26
US$1.80
+42.9%
41.6%US$3.00US$1.00n/a5
Apr ’25US$1.26
US$1.80
+42.9%
41.6%US$3.00US$1.00n/a5
Mar ’25US$1.24
US$6.17
+397.3%
158.7%US$28.00US$1.00n/a6
Feb ’25US$1.20
US$6.17
+413.9%
158.7%US$28.00US$1.00n/a6
Jan ’25US$1.05
US$6.81
+548.8%
124.8%US$28.00US$1.00n/a8
Dec ’24US$0.90
US$7.57
+737.9%
116.6%US$28.00US$1.00US$4.077
Nov ’24US$5.09
US$29.78
+485.0%
23.0%US$43.00US$20.00US$2.099
Oct ’24US$6.85
US$30.75
+348.9%
21.6%US$43.00US$20.00US$1.188
Sep ’24US$7.90
US$28.89
+265.7%
27.5%US$43.00US$16.00US$1.189
Aug ’24US$9.81
US$28.89
+194.5%
27.5%US$43.00US$16.00US$1.329
Jul ’24US$10.37
US$28.89
+178.6%
27.5%US$43.00US$16.00US$1.159
Jun ’24US$8.70
US$28.89
+232.1%
27.5%US$43.00US$16.00US$1.039
May ’24US$9.25
US$29.11
+214.7%
30.3%US$43.00US$11.00US$1.269
Apr ’24US$8.09
US$29.11
+259.8%
30.3%US$43.00US$11.00US$1.269
Mar ’24US$12.24
US$32.89
+168.7%
22.0%US$50.00US$25.00US$1.249
Feb ’24US$16.97
US$32.50
+91.5%
23.3%US$50.00US$25.00US$1.208
Jan ’24US$15.75
US$31.89
+102.5%
23.1%US$50.00US$25.00US$1.059
Dec ’23US$15.86
US$32.25
+103.3%
24.0%US$50.00US$25.00US$0.908

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/30 21:05
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Julian HarrisonBTIG
Louise ChenCantor Fitzgerald & Co.
Gavin Clark-GartnerEvercore ISI